Because of the incredible success of the Texas Shoot-out in past years, the NCCF has honored the Shoot-out by making it a donor advised fund in 2012 and for future years.
Los Angeles (PRWEB) August 07, 2012
The National Canine Cancer Foundation’s 3rd annual Texas Agility Shoot-Out attracted over 425 people and raised more than $43,000 at the event held on August 4, 2012 through August 5, 2012.
Enjoyed by dogs and their owners alike for three years running, the annual Texas Agility Shoot-out, hosted by Canines for a Cure, is one of the area’s most anticipated dog-oriented events with all proceeds benefitting the National Canine Cancer Foundation. Complete with tunnels and hurdles, the Shoot-out offers canines a chance to exemplify their athletic prowess.
In addition to the three rings of agility, the Shoot-out hosted a vendor area featuring Elimay, Petco, the National Canine Cancer Foundation, and others. Attendees also had the chance to win a stay at Hotel Palomar—a Condé ‘Nast “Hotel We Love” winner, gift baskets from John Paul Pet, and a Modern Dog Magazine subscription through a World Famous Texas Sized Raffle. In addition to the raffle and obstacle course, the Shoot-Out provided owners a moment to remember their loving dogs at the 2012 Memorial Wall presented by Elimay Supplements.
“Because of the incredible success of the Texas Shoot-out in past years, the NCCF has honored the Shoot-out by making it a donor advised fund in 2012 and for future years,” said Gary Nice, Founder and CEO of the National Canine Cancer Foundation. “This means 100 percent of the proceeds go directly to cancer research.”
Generously sponsored by Elimay Supplements in memory of the beloved bulldog, Eli May, the Memorial Wall at the 2012 Texas Agility Shoot-out gave owners a chance to share stories of their beloved dogs that passed away due to cancer. This year, the memory of one special dog provided a chance for all owners to remember their four-legged friends.
The 2011 Shoot-Out raised $43,000 and the National Canine Cancer Foundation again broke the $40,000 mark during this 2012 event, and hopes to surpass $50,000 in 2013.
For more information about Elimay Supplements, please visit: http://www.elimaysupplements.com.
At Elimay Supplements, we understand how dogs are loved as a member of the family. We understand the joy of their spirit, care, and company. Eli May was one such special dog whose owner wanted the best health for his beloved companion. He wished she would have a long, healthy, happy life with him.
We also understand poor health of furry companions. We understand suffering. When Eli May developed cancer, her owner cared for her, empathized with her pain and suffering, and was bereaved when she finally passed away. The loss of beloved Eli May inspired her owner to improve and enhance the overall quality of life of dogs and Elimay Supplements was founded in her honor.
At Elimay Supplements, we continue the ideals Eli May’s owner followed as he cared for her: to provide dogs with the best products without any compromise on quality and to help dogs have their best, fulfilling life.
The Elimay Supplements product line includes pet supplements such as soft fish-flavored gelatin capsules to help dogs who are fighting abnormal cell growth to detox, better their immunity, and enhance their quality of life with essential omegas and nutrients.
About The National Canine Cancer Foundation
The National Canine Cancer Foundation is a nationwide, contribution funded, 501 ©(3) non-profit corporation dedicated to eliminating Cancer as a major health issue in dogs by funding grants directly to Cancer researchers who are working to save lives, find cures, better treatments and accurate, cost effective diagnostic methods in dealing with canine Cancer.
The purpose of the Foundation’s Research Grant Program is to encourage and provide grant support for basic, pre-clinical and clinical research in high impact and innovative cancer research, which is intended to develop innovative approaches to a cure, treatment, diagnosis or prevention of cancers in dogs. The program fosters collaboration between basic and clinical scientists with the intent of enhancing the transfer of basic research findings to clinical usefulness.